Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
New shot aims to shrink dangerous heart plaque
Disease control Recruiting nowThis study is testing a new injectable drug, IMC-001, to see if it can safely reduce the volume of a dangerous type of soft plaque in the heart arteries of patients who recently had a heart attack or unstable angina. The trial will enroll 30 participants who are already receiving…
Phase: PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Breakthrough trial aims to control rare blood cancer
Disease control Recruiting nowThis study is testing whether adding a new drug called IMM01 to standard treatment (azacitidine) works better for adults newly diagnosed with a rare blood cancer called chronic myelomonocytic leukemia (CMML). The main goals are to see if more patients achieve complete remission a…
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
First test of new injection in healthy women begins
Knowledge-focused Recruiting nowThis is an early-stage study to check the safety and basic effects of a new injection called IMC-003. It will involve 56 healthy women who have gone through menopause. The main goal is to see how the body handles the drug and to identify any side effects.
Phase: PHASE1 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC